Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Vaxart ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vaxart's ebitda for the twelve months ending Sep 30, 2026 was $35.34M. For fiscal 2025 it was $26.65M. The highest annual figure on record is $26.65M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.65M | – |
| FY2024 | Dec 31, 2024 | -$57.44M | – |
| FY2023 | Dec 31, 2023 | -$74.72M | – |
| FY2022 | Dec 31, 2022 | -$108.78M | – |
| FY2021 | Dec 31, 2021 | -$68.54M | – |
| FY2020 | Dec 31, 2020 | -$27.46M | – |
| FY2019 | Dec 31, 2019 | -$12.19M | – |
| FY2018 | Dec 31, 2018 | -$18.55M | – |
| FY2016 | Jun 30, 2016 | -$25.10M | – |
| FY2015 | Jun 30, 2015 | -$18.40M | – |
| FY2014 | Jun 30, 2014 | -$9.10M | – |
| FY2013 | Jun 30, 2013 | -$19.10M | – |
| FY2012 | Jun 30, 2012 | -$19.80M | – |
| FY2009 | Dec 26, 2009 | -$17.47M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | -$16.01M | – |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$12.43M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $6.30M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $57.48M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$5.73M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$12.41M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$12.69M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$9.26M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$12.25M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$14.04M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$21.89M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$14.57M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$15.76M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$20.89M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$23.51M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$29.25M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$27.86M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$28.03M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$23.65M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$23.02M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$16.23M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$14.78M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$14.52M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$12.50M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$6.94M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$7.91M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$114.00K | -117.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$4.88M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$3.96M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$4.00M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $652.00K | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$3.36M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$4.94M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$6.85M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$3.40M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$20.00M | – |
See a number that looks wrong?